We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
DAINIPPON SUMITOMO PHARMA ANNOUNCES LURASIDONE PHASE III DATA IN PATIENTS WITH SCHIZOPHRENIA.
- Abstract
The article reports on the positive results acquired by Dainippon Sumitomo Pharma Co. Ltd. (DSP) from the first Phase 3 clinical trial of its lurasiodone that treats patients with schizophrenia. It says that the double-blind, placebo-controlled trial of lurasidone, which is consumed by 80 milligrams per day, is said to be more effective than placebo for treating acute schizophrenia. It adds that lurasidone was well-endured and exhibited a low discontinuation rate. It reveals that there were mild adverse events observed during the trial, which include tardive dyskinesia, drowsiness, and increased weight.
- Subjects
CLINICAL trials; DRUG efficacy; SUMITOMO Dainippon Pharma Co. Ltd.; SCHIZOPHRENIA treatment; BLIND experiment; PLACEBOS; ADVERSE health care events; TARDIVE dyskinesia; DROWSINESS; MEDICAL experimentation on humans
- Publication
Psychiatry (1550-5952), 2009, Vol 6, Issue 6, p10
- ISSN
1550-5952
- Publication type
Article